Rituximab

Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer.

Rituximab

NA

Ikgdar, Mabthera, Reditux, Ristova

NA

NA

The antibody leads to selective killing of B-cells, by b binds to the antigen CD20, predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas.

• Non-Hodgkin's Lymphoma (NHL) - The recommended dose is 375 mg/m² as an IV infusion at weekly intervals for a total of four doses.
• 375 mg/m² the day prior to the initiation of FC chemotherapy for CLL (Chronic Lymphocytic Leukemia)
• Rheumatoid Arthritis (RA) - The recommended dose is two-1000 mg intravenous infusions separated by 2 weeks.

For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

Fever, chills, infection, weakness, headache, abdominal pain, back pain, throat irritation and flushing. Increased cough, runny nose, asthma, difficulty in breathing and sinus inflammation. 

Rituximab may interact with biologics including anti-TNF-alpha blockers.

Rituximab is contraindicated in patients with immune e disorders, renal diseases, hepatic diseases including hepatitis B infections, breathing disorders, active infections, SLE, recent history of angina and heart rhythm disorder.

Store at 20-25°C.

Molecular weight

143859.7 Da

Molecular formula

C6416H9874N1688O1987S44

CAS number

174722-31-7

Precautions

• Avoid vaccination while taking this medication.
• It may cause dizziness, do not drive a car or operate machinery while taking this medication.